The COVID-19 pandemic is an unprecedented challenge for all healthcare systems worldwide. Gastroenterologists and clinicians who actively manage patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC), need to ensure they are taking steps to minimize the risk of infection for their patients.
Russell D. Cohen, MD, shares his expert perspective as an author of the recently published AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic. Dr. Cohen highlights emerging evidence and the potential risk of IBD patients for COVID-19, as well as recommendations for the treatment and management of patients with IBD during the coronavirus pandemic. In addition, he reviews the publicly accessible SECURE-IBD international registry and its impact tracking COVID-19 in patients with IBD. Dr. Cohen further discusses how to identify, appropriately manage, and monitor patients with UC who test positive for COVID-19, through the use of an algorithm to guide complex clinical decisions for those who are symptomatic with or without suspicion of active UC inflammation.
1.00 AANP Contact Hour
1.00 AMA PRA Category 1 CreditTM
1.00 ANCC Contact Hour
1.00 CA-BRN Contact Hour
This activity was developed for gastroenterologists, physician assistants, nurse practitioners, nurses and other healthcare providers who manage patients with inflammatory bowel disease.
This activity is supported by an educational grant from Pfizer Inc.
Russell D. Cohen, MD
Professor of Medicine, Pritzker School of Medicine
Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
The University of Chicago Medicine